[Sar1, Ile8]-Angiotensin II acetate activates both the NADPH and NADH oxidases, and stimulates superoxide anion formation in vascular smooth muscle cells. [Sar1, Ile8]-Angiotensin II acetate has multiple effects on vascular smooth muscle, including contra

Angiotensin II human acetate (DRVYIHPF acetate) is a vasoconstrictor that mainly acts on the AT1 receptor.

TRV055 acetate is a ligand of angiotensin II type 1 receptor and stimulates cellular Gq-mediated signaling.

TRV-120027 acetate is a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1 receptor) and engages -arrestins while blocking G-protein signaling.

Angiotensin 1-7 (Ang-(1-7)) acetate, an endogenous heptapeptide from the renin-angiotensin system (RAS), exhibits cardioprotective effects through its anti-inflammatory and anti-fibrotic activities in cardiac cells. It effectively inhibits purified canine ACE activity (IC 50 =0.65 μM) and serves as a local synergistic modulator of kinin-induced vasodilation by hindering ACE and facilitating nitric oxide release. Additionally, this compound prevents Ang II-induced proliferation and hypertrophy in smooth muscle cells, alongside demonstrating antiangiogenic and growth-inhibitory effects on the endothelium [1] [2] [3].

Saralasin acetate is a Non-selective angiotensin II antagonist.